B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
XFOR
X4ANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+98.0
Score
AI commentary
The latest primary-source event is clearly positive for trial execution and timing, but the company remains a low-coverage, milestone-driven biotech with sparse news flow. No reliable post-announcement price reaction, analyst revision, options, short-interest, or social-coverage data are available in the packet, so confidence remains moderate and monitoring-focused.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12catalystInsider open-market salesMedium impact
The president and executive chairman reported open-market sales totaling approximately $320,000 on August 12, 2026 at $4.4445 per share, creating a modest short-term sentiment overhang [#SEC-FORM4-2026-08-13].
2026-09-08eventFDA Type C meeting supports smaller 4WARD trialHigh impact
X4 reported a positive FDA Type C meeting outcome: the agency agreed that reducing the global 4WARD Phase 3 trial from 176 to 126 participants preserves adequate overall power and that the proposed safety database could support a potential sNDA [#SEC-8K-2026-09-08].
2026-12-31catalyst4WARD enrollment completionHigh impact
Management expects enrollment in the 4WARD chronic-neutropenia trial to complete by year-end 2026 following the sample-size reduction and CRO transition [#SEC-8K-2026-09-08]. Execution or slippage should remain a key trading driver.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology